In 2013, a therapy using induced pluripotent stem (iPS) cells progressed to the clinical trial stage in Japan. On February 28th, RIKEN and the Foundation for Biomedical Research and Innovation jointly applied for approval of a research project involving clinical trials of sheets of retinal pigment epithelium constructed from iPS cells derived from patients with age-related maculopathy. This project was reviewed by the committee of Health Science Council to review policies on clinical research involving human stem cells with an emphasis on safety and especially tumorigenesis. On June 26th, the Committee decided to approve this project with some provisos. If the Ministry of Health, Labor, and Welfare officially approves the project based on a decision by another committee on scientific technology, then the world's first clinical trial using material from patient-derived iPS cells may be conducted in the summer of 2014. This will bring Japan to the forefront of efforts to introduce a pioneering biomedical technology and benefit stem-cell therapies.
iPS cells were first generated from mouse mature skin cells by Prof. Shinya Yamanaka (Nobel laureate in 2012) of Kyoto University in Japan, and these cells have been used in basic studies worldwide. iPS cells have the ability to differentiate into various types of somatic cells and can be used to construct functional cell sheets and tissue for transplantation. In vivo studies have raised concerns about the usage of iPS cells in that they may induce the formation of tumors, but improved gene transfer method has helped to increase the safety of this technology. In August 2012, Prof. Yamanaka proposed establishment of a standard assay system and cell bank of iPS cells (1) . The RIKEN Bio-Resource Center began providing established iPS cells to nonprofit researchers. This system helps to enhance the quality and speed of iPS cell research. Basic studies have been performed using the cell bank system. The cell bank system is a promising way to store and maintain iPS cells derived from individual patients.
A large program was launched in Japan starting in 2012 to support several long-term projects to facilitate the clinical use of iPS cell therapies (Table 1) ; the program is budgeted tens of millions of dollars every year. One of these long-term projects is studying agerelated maculopathy, and the project is the first to apply to the government for approval of clinical trials. Agerelated maculopathy is the leading cause of permanent blindness in the elderly and affects the central area of the retina, which is essential for central and color vision (2,3). The current treatment, administration of an antivascular endothelial growth factor receptor drug such as bevacizumab, alleviates symptoms but does not cure the condition. Retinitis pigmentosa is the main cause of blindness or visual impairment, so replacement of diseased retinal cells should be an effective treatment. Over the past few years, a research group led by Dr.
Masayo Takahashi of the Center for Developmental

Summary
A research project involving sheets of retinal pigment epithelium constructed from iPS cells derived from patients with age-related maculopathy is one step closer to being approved for clinical trials by the Japanese Government. Now is the time to make therapies using iPS cells clinically available. Advances in stem-cell therapies have been early awaited worldwide for several decades now. The large program launched in 2012 in Japan with the support of the Japanese Government will play a key role in facilitating the clinical use of iPS cell therapies. Currently, the Ministry of Health, Labor, and Welfare of Japan is considering approval of clinical trials of sheets of retinal pigment epithelium constructed from iPS cells derived from patients with age-related maculopathy, and the Ministry's approval of clinical trials of a therapy for Parkinson's disease using iPS cell-derived neurons will soon be sought. "Now is the time to make therapies using iPS cells clinically available." 
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